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qual Renin-Angiotensin System
lockade in Heart Failure
e wish to comment, specifically, on Dr. Messerli’s remarks about
he value of dual renin-angiotensin system blockade in heart failure
1). There are only 2 prospectively designed, adequately sized, and
ppropriately powered trials that examined the effect of adding an
ngiotensin receptor blocker to background therapy, including an
ngiotensin-converting enzyme (ACE) inhibitor, in patients with
eart failure. Both showed a statistically significant and clinically
eaningful reduction in the primary or coprimary mortality-
orbidity composite outcome (2,3). Furthermore, the surrogate
enefits of angiotensin receptor blockers added to ACE inhibitors
moved in parallel” with the benefits on clinical outcome (4,5). The
ortality/morbidity benefits were seen despite the expected and
odest increase in risk of renal dysfunction, hyperkalemia, and
ypotension. Regulatory authorities decreed that the benefits
utweighed the risks sufficiently to lead to worldwide approval of
his combination for symptomatic patients with chronic heart
ailure and a low left ventricular ejection fraction, with appropriate
onitoring to minimize adverse effects (6). International guide-
ines committees also drew a conclusion that was different from
hat of Dr. Messerli (7). The most recent guidelines even gave the
ombination the strongest recommendation (Level of Evidence: A,
lass I) to prevent hospital admission for heart failure, a distress-
ng and prognostically important outcome in these higher-risk
atients remaining symptomatic despite treatment with an ACE
nhibitor (8,9). We believe that patients would be better off if
hysicians adhere to authoritative guidelines and apply the evi-
ence in practice.
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ual Renin-Angiotensin System
lockade and Kidney Disease
ased on the ONTARGET (Ongoing Telmisartan Alone and in
ombination with Ramipril Global Endpoint Trial) study dealing
ith renal outcomes (1), Messerli (2) concluded that albuminuria can
o longer be regarded as a valid surrogate end point in renal disease
nd that dual renin-angiotensin system (RAS) blockade is dead until
urther notice. Since these interpretations have major importance, a
eticulous analysis of the ONTARGET study findings is warranted.
The ONTARGET study was conducted in 25,620 participants
ith low risk of chronic progressive kidney disease, except the 263
atients wrongly enrolled with estimated glomerular filtration rate
eGFR) 30 ml/min/1.73 m2. The mean urinary albumin/
reatinine ratio was 0.81 mg/mmol (7.2 mg/g), mean eGFR 73.6
l/min/1.73 m2 with a sustained rate of decline 1 ml/min/year.
he primary renal end point was a composite of any dialysis,
oubling of serum creatinine, and death.
The need for dialysis was established arbitrarily with no pre-
etermined protocol, and data were assessed post-hoc with a
uestionnaire to all sites. Serum creatinine was measured locally,
nd the local methods were not calibrated to a standard. Change in
